Reply to thread

Message: <blockquote data-quote="dxx" data-source="post: 26113176" data-attributes="member: 386171">(Reuters) - British drugmaker AstraZeneca <a href="https://www.reuters.com/companies/AZN.L" target="_blank">AZN.L</a> said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.<img src="https://i.imgur.com/Xv8Dh0v.jpg" alt="" class="fr-fic fr-dii fr-draggable " style="" />The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.“In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant,” an AstraZeneca spokesman said in response to the FT report.<a href="https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-varian-idUSKBN2A60RH?utm_campaign=trueAnthem%3A+Trending+Content&utm_medium=trueAnthem&utm_source=facebook" target="_blank">https://www.reuters.com/article/uk-health-coronavirus-astrazeneca-varian-idUSKBN2A60RH?utm_campaign=trueAnthem:+Trending+Content&utm_medium=trueAnthem&utm_source=facebook</a></blockquote>

Verification: Hata thunen beduwama keeyada? (60 bedeema thuna)

Top Bottom